Aytu BioScience Interest Expense 2011-2026 | AYTU

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Aytu BioScience

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-512 K	870 K	184 K	-757 K	-2.05 M	2.61 M	536 K	749 K	2.53 M	5.49 M	115 K	-45.6 K	4.9 K	3.32 K	3.18 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
5.49 M	-2.05 M	649 K

Quarterly Interest Expense Aytu BioScience

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
190 K	201 K	-	36 K	140 K	542 K	-	70 K	96 K	584 K	-	-1.22 M	-1.23 M	-1.08 M	-2.54 M	-32 K	-257 K	-40 K	-516 K	-425 K	-379 K	752 K	-	539 K	447 K	195 K	642 K	195 K	128 K	76.6 K	128 K	76.6 K	197 K	189 K	197 K	189 K	388 K	415 K	388 K	415 K	240 K	113 K	240 K	113 K	37.5 K	37.3 K	692	463	1.5 K	3.44 K	1.31 K	1.5 K	1.03 K	855	855	1.03 K	791	2.38 K	694	-791

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
752 K	-2.54 M	8.84 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Amphastar Pharmaceuticals AMPH	23 K	$ 21.75	1.59 %	$ 1.02 B	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	1.82 M	$ 22.29	1.5 %	$ 3.69 B	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Brainstorm Cell Therapeutics BCLI	-93 K	-	-2.5 %	$ 5.88 M	USA
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
BioNTech SE BNTX	14.2 M	$ 102.75	-2.57 %	$ 27.2 B	Germany
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Aquestive Therapeutics AQST	6.55 M	$ 4.1	0.37 %	$ 438 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 23.2	-0.26 %	$ 2.95 B	USA
Autolus Therapeutics plc AUTL	36.7 M	$ 1.42	-1.39 %	$ 378 M	Britain
Can-Fite BioPharma Ltd. CANF	227 K	$ 2.99	2.75 %	$ 4.92 M	Israel
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
bluebird bio BLUE	16.4 M	-	-	$ 546 M	USA
ContraFect Corporation CFRX	-4.81 M	-	-5.16 %	$ 5.39 M	USA
Cardiff Oncology CRDF	5 K	$ 1.72	-0.29 %	$ 115 M	USA
BioXcel Therapeutics BTAI	-3.52 M	$ 1.07	0.94 %	$ 13.1 M	USA
Cabaletta Bio CABA	2 M	$ 2.96	0.17 %	$ 297 M	USA
Cara Therapeutics CARA	7.16 M	-	-3.03 %	$ 260 M	USA
Esperion Therapeutics ESPR	3.49 M	$ 1.95	1.83 %	$ 405 M	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
CASI Pharmaceuticals CASI	2.9 K	-	-	$ 35.4 M	USA